QGP Short: Increased FDA Enforcement of Drug Advertising Requirements
Update: 2025-09-23
Description
The FDA is cracking down — hard — on misleading drug advertising across TV, social media, and digital platforms.
Why? Too many ads are pushing benefits while burying risks — or skipping fair balance entirely. Influencer campaigns, compounded drug promos, and telehealth ads are under the microscope. As a result, we’ve seen hundreds of warning letters and cease-and-desist letters having already been issued.
In this Quality Grind Short, Mike talks about ways to prevent your products from becoming the subject of unfounded claims or non-compliant communication of health benefits and risks.
Contact MEDVACON:
- Message us at @MedvaconLifeSciences on LinkedIn
- Visit our website at www.medvacon.com/contact
- Email us at qualitygrind@medvacon.com
Thanks for listening! Don't forget to follow us @medvacon on all platforms for updates on blogs and podcasts!
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
